0718 GMT - Novartis's trial results for its ianalumab drug candidate in autoimmune disorder Sjoegren's disease suggests the company's next pipeline in a pill--or a drug marketed for multiple indications--could be under way, Vontobel's Stefan Schneider says in a research note. The Swiss pharmaceutical company said it is testing the drug in other diseases. Ianalumab worked in two late-stage trials and this could pave the way for a systematic treatment for a disease for which there are only limited symptomatic treatments available at the moment, the analyst says. This could increase the diagnosis rate, as the scientific literature estimates 50% of patients are undiagnosed, the analyst says. Vontobel estimates peak sales for the drug at $1 billion. Novartis shares rise 2.3%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
August 11, 2025 03:18 ET (07:18 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。